Therapeutic Response

v::ALK status confers therapeutic sensitivity to Crizotinib in patients with Anaplastic Large Cell Lymphoma.

Statements

Source and description
Xalkori (crizotinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).
Xalkori (crizotinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.